Please ensure Javascript is enabled for purposes of website accessibility

Accountants Close Review of Valeant, Send Shares Soaring 10%

By Todd Campbell - Apr 5, 2016 at 4:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A review of the company's accounting has come to a close with no new surprises.

Image source: Flickr user

What: After reporting that its internal investigation of its accounting practices has come to a close, and amid reports that it's sweetening its offer to debt holders, shares of Valeant Pharmaceuticals (BHC -5.82%) jumped 10.3% today. 

So what: This morning, Valeant Pharmaceuticals announced that an ad hoc committee of its Board of Directors are putting the wraps on a review of accounting practices. Previously, the committee discovered that Valeant had incorrectly reported $58 million in sales in 2014 that it also recorded on its books in 2015.

The accounting mishap stemmed from its now-shuttered deal with Philidor, a specialty pharmacy that distributed Valeant drugs and that Valeant had arranged to acquire. Prior to inking a deal that would give it control of Philidor, Valeant recorded revenue from its drugs when sales were made to Philidor, rather than when Philidor sold those drugs to patients. After making its agreement with Philidor, the company should have swapped to recording revenue when sales were made to patients. The company failed to do that in 2014, but it recorded those sales properly in 2015.

Valeant's ad hoc committee found no additional problems beyond that previously reported mistake, thus alleviating concerns that another shoe could drop at the embattled company. Because the company couldn't file audited financials with the SEC until the review finished, its coming to an end is a major milestone.

Now what: Getting its financials up to date with the SEC is critical because a failure to do so by month's end could have allowed debt holders of $30.9 billion in long-term liabilities to cry default. Now that the review is complete, management says it's on track to deliver those documents to the SEC by April 29.

Additionally, Reuters reports that Valeant is offering to boost the interest it's paying on its debt in order to secure support from its debt holders. According to Reuters, Valeant will pay an additional point of interest on its debt, with the rate being paid as long as leverage exceeds 1.75. Currently, Valeant's leverage ratio is 5.8. The agreement also calls for any proceeds from asset sales to be used to pay down debt as long as the company remains out of compliance in filing its financials with regulators and it has a leverage ratio at or below 4.5.

At this time, it's not confirmed that bond holders will accept this deal, but it is good news that negotiations that could shore up its financial position are happening.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
$9.22 (-5.82%) $0.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.